�ݺ�ߣshows by User: RobyZomer

�ݺ�ߣshows by User: RobyZomer / http://www.slideshare.net/images/logo.gif �ݺ�ߣshows by User: RobyZomer / Tue, 06 Nov 2018 07:07:40 GMT �ݺ�ߣShare feed for �ݺ�ߣshows by User: RobyZomer Nitin Mantri of RMIT at CannaTech 2018 Sydney /slideshow/nitin-mantri-of-rmit-at-cannatech-2018-sydney/122064741 cannatechmantrishort-181106070740
From our VP of Business Development Ron Lipsky: "A great honor and pleasure to share the stage with Nitin Mantri of RMIT at CannaTech 2018 Sydney! We spoke about the importance of collaboration between academia and industry and our RMIT University Umbrella agreement and exciting scientific collaborations..."]]>
From our VP of Business Development Ron Lipsky: "A great honor and pleasure to share the stage with Nitin Mantri of RMIT at CannaTech 2018 Sydney! We spoke about the importance of collaboration between academia and industry and our RMIT University Umbrella agreement and exciting scientific collaborations..."]]> Tue, 06 Nov 2018 07:07:40 GMT /slideshow/nitin-mantri-of-rmit-at-cannatech-2018-sydney/122064741 RobyZomer@slideshare.net(RobyZomer) Nitin Mantri of RMIT at CannaTech 2018 Sydney RobyZomer From our VP of Business Development Ron Lipsky: "A great honor and pleasure to share the stage with Nitin Mantri of RMIT at CannaTech 2018 Sydney! We spoke about the importance of collaboration between academia and industry and our RMIT University Umbrella agreement and exciting scientific collaborations..." <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/cannatechmantrishort-181106070740-thumbnail.jpg?width=120&height=120&fit=bounds" /><br> From our VP of Business Development Ron Lipsky: "A great honor and pleasure to share the stage with Nitin Mantri of RMIT at CannaTech 2018 Sydney! We spoke about the importance of collaboration between academia and industry and our RMIT University Umbrella agreement and exciting scientific collaborations..."

Nitin Mantri of RMIT at CannaTech 2018 Sydney from Roby Zomer

]]> 447 1 https://cdn.slidesharecdn.com/ss_thumbnails/cannatechmantrishort-181106070740-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Wells Haslem Mayhew's report on the Derma survey /slideshow/wells-haslem-mayhews-report-on-the-derma-survey/75633632 170427reporthempsurvey-170503104649
A REPORT INTO HEMP BUSINESS AND CUSTOMERS IN AUSTRALIA: HOW WOULD POTENTIAL CHANGES TO HEMP SCHEDULING AFFECT THE INDUSTRY? MGC Derma commissioned Wells Haslem Mayhew to undertake a survey of hemp related businesses and consumers in Australia in April 2017. The purpose of the survey was to ascertain the impact the proposed changes to hemp scheduling would have on business and consumers. On 2 February the scheduling delegates released an interim decision outlining proposed amendments to the entries for cannabis, tetrahydrocannabinols (THC) and cannabidiol (CBD) in the SUSMP. If these proposed changes go ahead and are adopted by the States and Territories, they will have the practical effect of rendering a number of currently legal low-THC hemp products, including cosmetics and topical ointments containing hemp oil, unlawful. Due to the impending TGA decision due in May, the survey was opened to respondents for two weeks, limiting the number of responses. In saying that, we did receive 482 responsesin total, including various calls from concerned business owners and industry representatives. Our data demonstrates clearly that there would be significant impacts on Australian business if the TGA was to go ahead with proposed changes to cannabis scheduling. ]]>
A REPORT INTO HEMP BUSINESS AND CUSTOMERS IN AUSTRALIA: HOW WOULD POTENTIAL CHANGES TO HEMP SCHEDULING AFFECT THE INDUSTRY? MGC Derma commissioned Wells Haslem Mayhew to undertake a survey of hemp related businesses and consumers in Australia in April 2017. The purpose of the survey was to ascertain the impact the proposed changes to hemp scheduling would have on business and consumers. On 2 February the scheduling delegates released an interim decision outlining proposed amendments to the entries for cannabis, tetrahydrocannabinols (THC) and cannabidiol (CBD) in the SUSMP. If these proposed changes go ahead and are adopted by the States and Territories, they will have the practical effect of rendering a number of currently legal low-THC hemp products, including cosmetics and topical ointments containing hemp oil, unlawful. Due to the impending TGA decision due in May, the survey was opened to respondents for two weeks, limiting the number of responses. In saying that, we did receive 482 responsesin total, including various calls from concerned business owners and industry representatives. Our data demonstrates clearly that there would be significant impacts on Australian business if the TGA was to go ahead with proposed changes to cannabis scheduling. ]]> Wed, 03 May 2017 10:46:49 GMT /slideshow/wells-haslem-mayhews-report-on-the-derma-survey/75633632 RobyZomer@slideshare.net(RobyZomer) Wells Haslem Mayhew's report on the Derma survey RobyZomer A REPORT INTO HEMP BUSINESS AND CUSTOMERS IN AUSTRALIA: HOW WOULD POTENTIAL CHANGES TO HEMP SCHEDULING AFFECT THE INDUSTRY? MGC Derma commissioned Wells Haslem Mayhew to undertake a survey of hemp related businesses and consumers in Australia in April 2017. The purpose of the survey was to ascertain the impact the proposed changes to hemp scheduling would have on business and consumers. On 2 February the scheduling delegates released an interim decision outlining proposed amendments to the entries for cannabis, tetrahydrocannabinols (THC) and cannabidiol (CBD) in the SUSMP. If these proposed changes go ahead and are adopted by the States and Territories, they will have the practical effect of rendering a number of currently legal low-THC hemp products, including cosmetics and topical ointments containing hemp oil, unlawful. Due to the impending TGA decision due in May, the survey was opened to respondents for two weeks, limiting the number of responses. In saying that, we did receive 482 responsesin total, including various calls from concerned business owners and industry representatives. Our data demonstrates clearly that there would be significant impacts on Australian business if the TGA was to go ahead with proposed changes to cannabis scheduling. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/170427reporthempsurvey-170503104649-thumbnail.jpg?width=120&height=120&fit=bounds" /><br> A REPORT INTO HEMP BUSINESS AND CUSTOMERS IN AUSTRALIA: HOW WOULD POTENTIAL CHANGES TO HEMP SCHEDULING AFFECT THE INDUSTRY? MGC Derma commissioned Wells Haslem Mayhew to undertake a survey of hemp related businesses and consumers in Australia in April 2017. The purpose of the survey was to ascertain the impact the proposed changes to hemp scheduling would have on business and consumers. On 2 February the scheduling delegates released an interim decision outlining proposed amendments to the entries for cannabis, tetrahydrocannabinols (THC) and cannabidiol (CBD) in the SUSMP. If these proposed changes go ahead and are adopted by the States and Territories, they will have the practical effect of rendering a number of currently legal low-THC hemp products, including cosmetics and topical ointments containing hemp oil, unlawful. Due to the impending TGA decision due in May, the survey was opened to respondents for two weeks, limiting the number of responses. In saying that, we did receive 482 responsesin total, including various calls from concerned business owners and industry representatives. Our data demonstrates clearly that there would be significant impacts on Australian business if the TGA was to go ahead with proposed changes to cannabis scheduling.

Wells Haslem Mayhew's report on the Derma survey from Roby Zomer

]]> 657 5 https://cdn.slidesharecdn.com/ss_thumbnails/170427reporthempsurvey-170503104649-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Clinical evidence for medicinal cannabis report /slideshow/clinical-evidence-for-medicinal-cannabis-report/72264883 clinicalevidenceformedicinalcannabisreportdigital-170217101006
A Report Developed by the University of Sydney Community Placement Program in Partnership with MGC Pharmaceuticals, In recent years, medicinal cannabis has gone from being a niche and obscure area of medical scientific research into “one of the fastest moving frontiers in pharmacology”. The potential value of cannabis as medicine has been demonstrated in relation to a number of serious conditions and symptoms including cancer, epilepsy, multiple sclerosis, chronic pain, muscle spasticity and nausea. The clinical evidence regarding medicinal cannabis has received less attention than it merits, and scientists, clinicians, patients and carers seeking access to this evidence have found it difficult to separate good research from the wealth of anecdotal and less rigorously obtained experimental results. This report aims to summarise the strongest available scientific research on the use of cannabis as a medicine for the treatment of epilepsy, cancer and multiple sclerosis; the symptoms of these conditions; and the side-effects of their current treatment. ]]>
A Report Developed by the University of Sydney Community Placement Program in Partnership with MGC Pharmaceuticals, In recent years, medicinal cannabis has gone from being a niche and obscure area of medical scientific research into “one of the fastest moving frontiers in pharmacology”. The potential value of cannabis as medicine has been demonstrated in relation to a number of serious conditions and symptoms including cancer, epilepsy, multiple sclerosis, chronic pain, muscle spasticity and nausea. The clinical evidence regarding medicinal cannabis has received less attention than it merits, and scientists, clinicians, patients and carers seeking access to this evidence have found it difficult to separate good research from the wealth of anecdotal and less rigorously obtained experimental results. This report aims to summarise the strongest available scientific research on the use of cannabis as a medicine for the treatment of epilepsy, cancer and multiple sclerosis; the symptoms of these conditions; and the side-effects of their current treatment. ]]> Fri, 17 Feb 2017 10:10:06 GMT /slideshow/clinical-evidence-for-medicinal-cannabis-report/72264883 RobyZomer@slideshare.net(RobyZomer) Clinical evidence for medicinal cannabis report RobyZomer A Report Developed by the University of Sydney Community Placement Program in Partnership with MGC Pharmaceuticals, In recent years, medicinal cannabis has gone from being a niche and obscure area of medical scientific research into “one of the fastest moving frontiers in pharmacology”. The potential value of cannabis as medicine has been demonstrated in relation to a number of serious conditions and symptoms including cancer, epilepsy, multiple sclerosis, chronic pain, muscle spasticity and nausea. The clinical evidence regarding medicinal cannabis has received less attention than it merits, and scientists, clinicians, patients and carers seeking access to this evidence have found it difficult to separate good research from the wealth of anecdotal and less rigorously obtained experimental results. This report aims to summarise the strongest available scientific research on the use of cannabis as a medicine for the treatment of epilepsy, cancer and multiple sclerosis; the symptoms of these conditions; and the side-effects of their current treatment. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/clinicalevidenceformedicinalcannabisreportdigital-170217101006-thumbnail.jpg?width=120&height=120&fit=bounds" /><br> A Report Developed by the University of Sydney Community Placement Program in Partnership with MGC Pharmaceuticals, In recent years, medicinal cannabis has gone from being a niche and obscure area of medical scientific research into “one of the fastest moving frontiers in pharmacology”. The potential value of cannabis as medicine has been demonstrated in relation to a number of serious conditions and symptoms including cancer, epilepsy, multiple sclerosis, chronic pain, muscle spasticity and nausea. The clinical evidence regarding medicinal cannabis has received less attention than it merits, and scientists, clinicians, patients and carers seeking access to this evidence have found it difficult to separate good research from the wealth of anecdotal and less rigorously obtained experimental results. This report aims to summarise the strongest available scientific research on the use of cannabis as a medicine for the treatment of epilepsy, cancer and multiple sclerosis; the symptoms of these conditions; and the side-effects of their current treatment.

Clinical evidence for medicinal cannabis report from Roby Zomer

]]> 782 10 https://cdn.slidesharecdn.com/ss_thumbnails/clinicalevidenceformedicinalcannabisreportdigital-170217101006-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 MGC DERMA CBD COSMETICS /slideshow/mgc-derma-cbd-cosmetics/64103525 page18filesmerged-160717194751
MGC’s products catalogue is presenting a uniquely formulated to offer the maximum anti-ageing, antioxidant, and autoimmune benefits derived from its high-purity natural CBD. MGC DERMA, the cosmetics division of MGC PHARMACUTICALS, an Australian public company (ASX:MXC), which was established in 2015 by leading industry executives, with the goal to create a global natural treatments platform. MGC’s business is centred on the growing of high CBD yielding Hemp in Europe.]]>
MGC’s products catalogue is presenting a uniquely formulated to offer the maximum anti-ageing, antioxidant, and autoimmune benefits derived from its high-purity natural CBD. MGC DERMA, the cosmetics division of MGC PHARMACUTICALS, an Australian public company (ASX:MXC), which was established in 2015 by leading industry executives, with the goal to create a global natural treatments platform. MGC’s business is centred on the growing of high CBD yielding Hemp in Europe.]]> Sun, 17 Jul 2016 19:47:51 GMT /slideshow/mgc-derma-cbd-cosmetics/64103525 RobyZomer@slideshare.net(RobyZomer) MGC DERMA CBD COSMETICS RobyZomer MGC’s products catalogue is presenting a uniquely formulated to offer the maximum anti-ageing, antioxidant, and autoimmune benefits derived from its high-purity natural CBD. MGC DERMA, the cosmetics division of MGC PHARMACUTICALS, an Australian public company (ASX:MXC), which was established in 2015 by leading industry executives, with the goal to create a global natural treatments platform. MGC’s business is centred on the growing of high CBD yielding Hemp in Europe. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/page18filesmerged-160717194751-thumbnail.jpg?width=120&height=120&fit=bounds" /><br> MGC’s products catalogue is presenting a uniquely formulated to offer the maximum anti-ageing, antioxidant, and autoimmune benefits derived from its high-purity natural CBD. MGC DERMA, the cosmetics division of MGC PHARMACUTICALS, an Australian public company (ASX:MXC), which was established in 2015 by leading industry executives, with the goal to create a global natural treatments platform. MGC’s business is centred on the growing of high CBD yielding Hemp in Europe.

MGC DERMA CBD COSMETICS from Roby Zomer

]]> 229 3 https://cdn.slidesharecdn.com/ss_thumbnails/page18filesmerged-160717194751-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 https://cdn.slidesharecdn.com/profile-photo-RobyZomer-48x48.jpg?cb=1712306111 Without music, life would be a mistake. http://www.greencityltd.com https://cdn.slidesharecdn.com/ss_thumbnails/cannatechmantrishort-181106070740-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/nitin-mantri-of-rmit-at-cannatech-2018-sydney/122064741 Nitin Mantri of RMIT a... https://cdn.slidesharecdn.com/ss_thumbnails/170427reporthempsurvey-170503104649-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/wells-haslem-mayhews-report-on-the-derma-survey/75633632 Wells Haslem Mayhew's ... https://cdn.slidesharecdn.com/ss_thumbnails/clinicalevidenceformedicinalcannabisreportdigital-170217101006-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/clinical-evidence-for-medicinal-cannabis-report/72264883 Clinical evidence for ...